Equities analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to post $240,000.00 in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Abeona Therapeutics’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $300,000.00. Abeona Therapeutics posted sales of $260,000.00 in the same quarter last year, which suggests a negative year over year growth rate of 7.7%. The company is scheduled to report its next quarterly earnings report on Friday, March 30th.
On average, analysts expect that Abeona Therapeutics will report full year sales of $240,000.00 for the current financial year, with estimates ranging from $800,000.00 to $900,000.00. For the next fiscal year, analysts expect that the firm will report sales of $1.21 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.22 million. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%.
Several research firms have weighed in on ABEO. Cantor Fitzgerald lifted their price objective on Abeona Therapeutics from $21.00 to $34.00 and gave the company an “overweight” rating in a research report on Wednesday, October 11th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective (up from $20.00) on shares of Abeona Therapeutics in a research report on Monday, October 9th. Citigroup began coverage on Abeona Therapeutics in a research report on Tuesday, October 10th. They set a “buy” rating and a $32.00 price objective on the stock. ValuEngine cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 23rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $26.40.
Abeona Therapeutics (NASDAQ:ABEO) traded up $0.40 during trading on Thursday, reaching $15.65. The company’s stock had a trading volume of 780,059 shares, compared to its average volume of 750,183. The company has a market cap of $732.03, a PE ratio of -24.08 and a beta of 2.34. Abeona Therapeutics has a fifty-two week low of $4.50 and a fifty-two week high of $22.75.
Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in shares of Abeona Therapeutics in the 4th quarter worth approximately $218,000. Rhumbline Advisers bought a new stake in shares of Abeona Therapeutics in the 2nd quarter worth approximately $190,000. Wells Fargo & Company MN boosted its position in shares of Abeona Therapeutics by 3,421.8% in the 3rd quarter. Wells Fargo & Company MN now owns 35,218 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 34,218 shares in the last quarter. Family Management Corp boosted its position in shares of Abeona Therapeutics by 50.0% in the 3rd quarter. Family Management Corp now owns 36,000 shares of the biopharmaceutical company’s stock worth $614,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of Abeona Therapeutics in the 2nd quarter worth approximately $264,000. 41.97% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/02/240000-00-in-sales-expected-for-abeona-therapeutics-inc-abeo-this-quarter.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.